eukin 12 production in patients with chronic active Crohn’s disease [J]. Gut.2002;50:196–200 .РTNF- 肿瘤坏死因子;TH -T 辅助细胞;?IL - 白介素;IFN - 干扰素;NF - 核因子; ?HIMEC - 人肠微血管内皮细胞Р沙利度胺治疗UC的早期研究Р入组患者均为糖皮质激素耐药或依赖,入组22名患者,其中9例为管型(luminal disease),13例为肛周瘘?CDAI>150,起始剂量为300mg bedtime或200mg bedtime?第4和12周通过CDAI对患者进行评估Р4.Thalidomide Therapy for Patients With Refractory Crohn’s Disease: An Open-Label Trial[J]. ? GASTROENTEROLOGY 1999;117:1271–1277 .РCDAI指数的定义:? 150-220为轻度活动;220-450为中度活动;? >450为重度活动;<150为临床缓解Р沙利度胺治疗UC的早期研究Р4周:Three (33%) of the luminal patients responded, and all were in clinical remission. Nine (69%) of the patients with fistulas responded; 3 (23%) achieved remission. The median CDAI score of all study patients at 4 weeks was 210 (range, 50–381 in remaining patients; P <0.pared with baseline).
全文预览
